Lancet Haematol. 2024 Apr 24:S2352-3026(24)00097-8. doi: 10.1016/S2352-3026(24)00097-8. Online ahead of print.
NO ABSTRACT
PMID:38677301 | DOI:10.1016/S2352-3026(24)00097-8
Recent Content
- Multiple Myeloma With Idiopathic Intracranial Hypertension
- Multiple myeloma complicated with light chain cast nephropathy with focal amyloidosis: A case report
- Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)
- The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
- Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties
- A Neurocritical Case Study of Intracerebral Hemorrhage Unveiling Multiple Myeloma Through the Lens of Hickam’s Dictum
- Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
- Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs
- Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
- Effects on the Physical Functioning of Two Exercise Interventions in Patients with Multiple Myeloma: A Pilot Feasibility Study